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aBstraCt
introduCtion. The aim of the study is to investigate the ability of an amniotic membrane implant combined with 
penetrating keratoplasty to reduce early and mid-term complications in complex cases such as penetrating burns, 
infective ulcers, keratitis, or corneal graft failure. 
MateriaLs and Methods. Fifty patients: 12 with keratitis, 24 with infective ulcers, 10 with penetrating trauma, 
and four with a history of corneal graft failure, were divided into two groups. The first group of 25 patients (Group 
A) underwent penetrating keratoplasty alone, while the second group of 25 patients (Group B) received penetrating 
keratoplasty associated with an amniotic membrane implant. Amniotic membrane implantation was performed in 
a ‘patch modality’, and the membrane was sewn to the graft with the epithelium/basement membrane side facing 
inwards. All patients were evaluated, respectively, 3, 15, 30, 90, and 180 days after surgery. At each visit a slit-lamp 
examination was performed together with corneal thickness and endothelial cell count assessment. All the data were 
subjected to statistical analysis with Student’s t-test. 
resuLts. At the slit-lamp examination in Group A  48% of patients showed Descemet folds at one and three 
months, respectively, while 80% of patients of Group B did not show any Descemet folds. In Group A we registered 
two cases of early graft failure and two cases of shallow anterior chamber, while none of these complications appeared 
in Group B. In Group A the average corneal thickness at 15, 30, 90, and 180 days post-operatively was, respectively, 
695 ± 43 µm, 658 ± 31 µm, 588 ± 12 µm, and 518 ± 20 µm, while in Group B it was found to be, respectively, 
667 ± 12 µm, 632 ± 17 µm, 562 ± 16 µm, and 516 ± 10 µm. Differences in corneal thickness between Group A and 
Group B were found to be statistically significant (p = 0.05). Endothelial cell count was in Group A 2582 c/mm2 at 
15 days, 2500 c/mm2 at one month, 2335 c/mm2 at three months, and 2111 c/mm2 at six months, while the average 
count for Group B patients was 2607 c/mm2, 2503 c/mm2, 2299 c/mm2, and 2086 c/mm2, respectively. Differences 
in endothelial cell count between the two groups did not show any statistical significance (p > 0.05).
ConCLusions. Amniotic membrane implantation associated with penetrating keratoplasty reduces early and 
mid-term complications of corneal grafts in patients with high risk of failure. This positive effect may be due to the 
anti-inflammatory, neurotrophic, and anti-angiogenetic properties of the amniotic membrane. Longer observation 
and larger case series can be useful in evaluation of the functional outcome of grafts in these patients.
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introduCtion
The regular post-operative course of penetrating 
keratoplasty surgery (PK) may be affected by short- 
and medium-term complications such as delay in 
re-epithelialisation, persistence of corneal oedema, 
shallow anterior chamber, inflammation of corneal 
epithelium, and, above all, graft rejection. These 
complications are more frequent in patients in 
whom PK is meant to treat “complex” clinical and 
anatomical situations such as corneal opacity from 
perforating injury, corneal neovascularisation due to 
inflammatory or infectious processes, and rejection 
of previous PK treatments. In these situations, graft 
survival is endangered by an excessive inflammatory 
response as long as functional deficiencies that may 
lead to graft rejection. To reduce inflammatory re-
sponse and to minimise epithelial defects connected 
to stem cell deficiency, an amniotic membrane im-
plant may help graft survival and reduce postop-
erative complications. Amniotic membrane (AM) 
has anti-inflammatory, neurotrophic, and anti-an-
giogenic properties, and it is used in several oph-
thalmologic situations [1–4]. The objective of this 
study is to investigate if the application of amniotic 
membrane associated with penetrating keratoplasty 
surgery could help managing patients with “com-
plex” corneal pathologies. 
MateriaLs and Methods
Fifty patients (30 men and 20 women) par-
ticipated in our study, with an average age of 
62.3 years. All patients presented severe corneal 
opacities due to (Fig. 1):
 — Prior keratitis (12 cases)
 — Prior corneal ulcer (24 cases)
 — Prior penetrating trauma of the anterior segment 
(10 cases)
 — History of graft failure (four cases)
The patients were randomised in a 1:1 ratio into 
two groups: the subjects in Group A (25 patients: 
five prior keratitis, 12 prior corneal ulcers, seven 
prior penetrating trauma, and one case of previous 
graft failure) underwent standard PK surgery, while 
subjects in Group B (25 patients: seven prior kera-
titis, 12 prior corneal ulcers, three prior penetrating 
trauma, and three cases of previous graft failure) 
underwent PK surgery associated with the appli-
cation of a single-layer amniotic membrane patch. 
Corneas used for surgery presented an average en-
dothelial cell density of 2720 cells/mm2 (range 
between 2400 and 2950 cells/mm2) while a single 
layer of AM was applied with the “patch method” 
(epithelium membrane facing the graft and stromal 
side facing outwards). The AM was sutured to the 
sclera using 10–0 nylon sutures and protected with 
a contact lens placed at the end of the surgery. The 
contact lens and amniotic membrane patch were 
removed 15 days after PK surgery. All patients 
were re-examined 3, 15, 30, 90, and 180 days 
after surgery with a slit-lamp examination. At 15, 
90, and 180 days after surgery both pachymetry 
and endothelium cell density (EM-3000, Tomey, 
Japan) were registered. The parameters evaluated at 
each visit were: corneal transparency and oedema 
of the graft; Seidel test and reduction of anterior 
chamber depth; inflammation of the anterior seg-
ment; epithelial and/or endothelial distress signs 
and early rejection signs. The statistical analysis of 
collected data was performed with Student’s t-test 
for paired data.
resuLts 
Three, 15, and 30 days after surgery 10 pa-
tients (40%) of Group A presented signs of super-
ficial punctate keratopathy, 12 patients presented 
Descemet folds (48%), and two subjects showed 
a shallow anterior chamber (Seidel positive). Three 
months after surgery Descemet folds persisted in 
five of the 12 initial cases, and two cases of early 
graft rejection were identified. In Group B De-
scemet folds were detected in only five patients (at 
30 days post-surgery), while no cases of shallow 
anterior chamber or early rejection were reported. 
In Group A  the average corneal thickness at 15, 
30, 90, and 180 days post-operatively was, respec-
tively, 695 ± 43 µm, 658 ± 31 µm, 588 ± 12 µm, 
and 518 ± 20 µm, while in Group B it was found 
to be, respectively, 667 ± 12 µm, 632 ± 17 µm, 
562 ± 16 µm, and 516 ± 10 µm (Fig. 2). Differ-
ences in corneal thickness between Group A  and 
Group B were found to be statistically significant 
(p = 0.05). Endothelial cell count in Group A was 
2582 c/mm2 at 15 days, 2500 c/mm2 at one month, 
2335 c/mm2 at three months, and 2111 c/mm2 at 
six months, while the average count for Group B pa-
tients was 2607 c/mm2, 2503 c/mm2, 2,299 c/mm2, 
and 2086 c/mm2, respectively. The percentage re-
duction in the number of endothelial cells in the 
first six months post-surgery was 18.4% in Group 
A and 19.9% in Group B. Differences in endotheli-
al cell count between the two groups did not show 
any statistical significance (p > 0.05).
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Figure 2. Postoperative mean corneal thickness (µ) in Group A vs. Group B
Figure 1. Causes for penetrating keratoplasty in our case series 
(50 subjects)
disCussion 
Regular post-operative course of penetrating ker-
atoplasty surgery may be affected by short- and me-
dium-term complications. In our experience these 
complications occur more frequently in those patients 
where an extensive damage to the ocular surface results 
in limbal stem cell deficiency [5, 6] (for example, in 
the case of recurrent corneal ulcers, prolonged inflam-
mation and infection of the cornea, traumas, etc.). In 
these cases attachment issues with the transplanted 
graft are frequently observed and may predispose the 
patient to inflammatory processes and early rejection 
due to the aforementioned limbal stem cell deficiency 
[7–10]. Attachment issues of the graft (such as graft 
early rejection) are revealed by the presence of areas 
of epithelial distress, Descemet folds, persistence of 
significant de-epithelialisation, stromal oedema, and 
reduced viability of vascular endothelial cells [11–14]. 
In all these situations the proper attachment of the 
graft to the recipient’s eye is endangered and the risk 
of graft rejection is greatly increased. Because these 
cases are relatively unresponsive to medical therapy, 
we hypothesised that AM application in combina-
tion with PK surgery could improve post-operative 
performance when compared with traditional PK 
surgery outcomes. AM application after PK surgery 
has been previously described, but no comparative 
studies have been published [15, 16]. AM application 
may in fact improve post-operative outcomes thanks 
to the restoration of an intact basement membrane 
on its epithelial side. This may promote prolifera-
tion, migration, and differentiation of epithelial cells 
while maintaining their clonogenicity [17–19]. On 
the other hand, the stromal surface may inhibit the 
proliferation of fibroblasts and inflammatory cells 
through the suppression of the TGF b signal and 
the release of protease inhibitors and growth factors 
[20–22]. This stromal ability may therefore prevent 
inflammation and fibrosis. Using the patch method 
for AM application (stromal side facing outwards) 
the corneal epithelium can achieve an intact basement 
membrane, which promotes growth beneath the AM 
graft and guarantees faster re-epithelialisation of the 
flap. Improving the re-epithelialisation of the flap is 
a  primary objective of post-operative management 
because it reduces infectious risk and prevents the 
fibrosis due to the neovascularisation connected to re-
peated re-epithelialisation attempts. Moreover, Group 
B patients demonstrate that AM application acts as 
an occlusive bandage and ensures normal anterior 
chamber depth and intraocular pressure (no cases of 
shallow anterior chamber). While the healing prop-
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erties of AM’s epithelial component act in the first 
post-operative phase the stromal cells regulate progress 
in the short-medium term through the inhibition of 
inflammation and fibrosis. These properties explain 
the faster resolution of oedema and Descemet folds 
observed in Group B patients. These hypotheses are 
demonstrated by the fact that, in Group B patients, 
not only did the Descemet folds resolve faster but also 
the thickness of the flap (indicative of the presence of 
oedema) reduced more quickly. At the time of AM 
removal (on the 15th day) there was in fact a major 
difference in the thickness of the flap between the 
two sample groups, which was maintained in the 
subsequent examinations. These differences in corneal 
thickness were statistically significant at the performed 
Student’s t-test for paired data (p = 0.05). Regarding 
corneal thickness, the patients who underwent AM 
application showed much more homogeneous data 
than the patients treated with PK alone. This effect 
is attributable to AM anti-inflammatory activity that 
was able to contain the flap’s inflammatory oedema. 
However, the percentage reduction of corneal thickness 
at 30, 90, and 180 days after surgery was similar in the 
two groups and was not statistical significant (p > 0.05). 
These outcomes indicate that AM’s anti-oedema effect 
is most notable during the initial membrane’s stabi-
lisation phase and it decreases in later months. Nev-
ertheless, early inflammation resolution decreases the 
risk of neovascularisation and early rejection and is 
therefore a very important property of the AM, which 
can help us to manage complex PK surgeries. Regard-
ing endothelium cell count, our research did not reveal 
any impact from AM. Assessment of the endothelial 
count showed, in fact, a progressive reduction in the 
cell population of the transplanted flap, which is com-
parable between the two groups in the early and late 
post-operative phase. 
ConCLusions
The results of our research suggest the possibility 
of using the restorative, anti-inflammatory, neuro-
trophic and anti-angiogenic properties of AM to 
boost the vitality of the transplanted flap and the 
functional recovery process of the cornea. AM ap-
plication may also reduce the risk of early rejection, 
re-epithelialisation failure, neovascularisation, an-
terior chamber depth reduction, and inflammatory 
processes of the transplanted flap.
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